BGLC Stock Tumbled Over 13% Today: Why Is VitaGuard Commercialization Agreement Drawing Investor Attention?
Synopsis
The partnership aims to support the planned commercialization of minimal residual disease testing in Southeast Asia.
BioNexus Gene Lab Corp. (BGLC) announced on Wednesday that it has entered into definitive agreements with Asia-based firms Fidelion Diagnostics Pte. and Tongshu Biotechnology, among other parties, to commercialize VitaGuard in Southeast Asia.
VitaGuard is a high-fidelity, tumor-naïve liquid-biopsy platform for minimal residual disease. Minimal residual disease (MRD) is a small number of cancer cells that remain in the body during or after treatment, which are undetectable by standard methods.
China-headquartered Tongshu Gene is the original developer of the VitaGuard technology. The firm is the manufacturing partner of Singapore-based Fidelion. The partnership aims to support the planned commercialization of MRD testing in Southeast Asia.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.